June 2014 | OncologyLive

CLL Researcher Excited About Outlook for CDK Inhibitors

July 17, 2014

Joseph Flynn, DO, MPH, focuses on the development of novel therapeutics for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in his research at The Ohio State University Comprehensive Cancer Center.

Novel Therapies, Strategies in Development for NSCLC

July 16, 2014

The treatment landscape for patients with non-small cell lung cancer (NSCLC) is poised to undergo dramatic changes, as novel immunotherapies, second-generation targeted therapies, and new maintenance strategies continue to show promise in clinical trials.

Lost in Translation: Objectivity Can Be Elusive in Clinical Trial Reporting

July 10, 2014

Although oncology researchers seek to describe the significance of clinical trial outcomes with scientific rigor, the terminology used to communicate those findings in the peer-reviewed literature sometimes falls short in conveying the impact that a given therapy may have on patients in a real-world scenario.

Communication Challenges Loom as Germline Versus Somatic Cancer Data Evolve

July 08, 2014

Essentially all members of the medical community, including the most "generalist" family practice physicians, are being required to understand and incorporate into their daily practice an ever-increasing quantity of information related to the broad realm of molecular medicine

New Methods of Boosting Response to Bladder Cancer Immunotherapy Explored

June 18, 2014

Although bacillus Calmette-Guérin (BCG) therapy has significantly improved outcomes for patients with non–muscle invasive bladder cancer since its introduction nearly 40 years ago, there is a pressing need to enhance responses to BCG and to distinguish which patients would respond to treatment early on in the course of therapy.

Nab-Paclitaxel Compares Favorably in Pancreatic Cost-Effectiveness Study

June 17, 2014

A regimen of nab-paclitaxel (Abraxane) and gemcitabine is a cost-effective option for the first-line treatment of patients with metastatic pancreatic cancer because it delivers a survival advantage at a price comparable to the cost of an existing combination therapy

Recognizing the Giants

June 07, 2014

We are pleased to present the second class of leading oncology specialists whom an esteemed advisory board has chosen to honor with our 2nd Annual Giants of Cancer Careâ„¢ awards.

2nd Annual Giants of Cancer Care Awards Honor Leading Researchers

May 30, 2014

The ballots are in, and 16 leading researchers whose discoveries have propelled the field of cancer treatment forward will be honored during the 2014 Giants of Cancer Care award ceremony on May 30 at Riva Restaurant on Navy Pier in Chicago.